Pharmacokinetic interactions of flunixin meglumine and enrofloxacin in dogs

被引:21
作者
Ogino, T [1 ]
Mizuno, Y [1 ]
Ogata, T [1 ]
Takahashi, Y [1 ]
机构
[1] Natl Vet Assay Labs, Tokyo 1858511, Japan
关键词
D O I
10.2460/ajvr.2005.66.1209
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Objective-To examine pharmacokinetic interactions of flunixin meglumine and enrofloxacin in dogs following simultaneously administered SC injections of these drugs. Animals-10 Beagles (4 males and 6 females). Procedure-All dogs underwent the following 3 drug administration protocols with a 4-week washout period between treatments: flunixin administration alone (1 mg/kg, SC); simultaneous administration of flunixin (1 mg/kg, SC) and enrofloxacin (5 mg/kg, SC); and enrofloxacin administration alone (5 mg/kg, SC). Blood samples were collected from the cephalic vein at 0.5, 0.75, 1, 1.5, 2, 3, 5, 8, 12, and 24 hours following SC injections, and pharmacokinetic parameters of flunixin and enrofloxacin were calculated from plasma drug concentrations. Results-Significant increases in the area under the curve (32%) and in the elimination half-life (29%) and a significant decrease (23%) in the elimination rate constant from the central compartment of flunixin were found following coadministration with enrofloxacin, compared with administration of flunixin alone. A significant increase (50%) in the elimination half-life and a significant decrease (21%) in the maximum plasma drug concentration of enrofloxacin were found following coadministration with flunixin, compared with administration of enrofloxacin alone. Conclusions and Clinical Relevance-The observed decrease in drug clearances as a result of coadministration of flunixin and enrofloxacin indicates that these drugs interact during the elimination phase. Consequently, care should be taken during the concomitant use of flunixin and enrofloxacin in dogs to avoid adverse drug reactions.
引用
收藏
页码:1209 / 1213
页数:5
相关论文
共 21 条
[1]  
ANDERSON KL, 1986, AM J VET RES, V47, P1366
[2]  
Bregante MA, 1999, AM J VET RES, V60, P1111
[3]  
Coakley M, 1999, AM J VET RES, V60, P1441
[4]  
DOW SW, 1990, AM J VET RES, V51, P1131
[5]  
El-Banna HA, 1999, DEUT TIERARZTL WOCH, V106, P400
[6]   Comparative susceptibilities of various animal-pathogenic mycoplasmas to fluoroquinolones [J].
Hannan, PCT ;
Windsor, GD ;
deJong, A ;
Schmeer, N ;
Stegemann, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (09) :2037-2040
[7]  
HARDIE EM, 1985, AM J VET RES, V46, P235
[8]  
JENSEN RC, 1990, AM J VET RES, V51, P591
[9]   PHARMACOKINETICS OF ENROFLOXACIN AND ITS METABOLITE CIPROFLOXACIN AFTER INTRAVENOUS AND ORAL-ADMINISTRATION OF ENROFLOXACIN IN DOGS [J].
KUNG, K ;
RIOND, JL ;
WANNER, M .
JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 1993, 16 (04) :462-468
[10]   Possible active transport mechanism in pharmacokinetics of flunixin-meglumin in rabbits [J].
Miyazaki, Y ;
Horii, Y ;
Ikenaga, N ;
Shimoda, M ;
Kokue, E .
JOURNAL OF VETERINARY MEDICAL SCIENCE, 2001, 63 (08) :885-888